Phenylbutazone and the horse--a review.
The clinical uses and side-effects of phenylbutazone in man, horses, and other animals are reviewed. The blood dyscrasias commonly described in man have not been reported in the horse, although several of the more minor side-effects have occasionally been seen (e.g. water retention, depression, transient staggering and phlebitis). Despite the lack of documented evidence, the toxicity of phenylbutazone in the horse is considered to be lower than that in man. This may be associated with the lower dose rates normally used, the more rapid plasma clearance rate and the comparatively younger age of most horses under treatment. The following guidelines for the use of phenylbutazone in practice are put toward. It should only be used under strict veterinary control and then only if there are clear clinical indications. It should not be given if there are signs of gastro-intestinal ulceration, clotting defects or any cardiac, renal or hepatic dysfunction. Dose rates should be kept to a minimum and the drug withdrawn immediately if any side-effects occur or if there is no clinical response within 4 days. If prolonged therapy is necessary, periodic haematological analyses should be carried out.
D000380:Agranulocytosis / Q000139:chemically induced / Q000662:veterinary; D000740:Anemia / Q000139:chemically induced / Q000662:veterinary; D000818:Animals; D002371:Cat Diseases / Q000139:chemically induced; D002415:Cats; D004283:Dog Diseases / Q000139:chemically induced; D004285:Dogs; D006734:Horse Diseases / Q000139:chemically induced / Q000188:drug therapy; D006736:Horses / Q000378:metabolism; D006801:Humans; D051379:Mice; D010653:Phenylbutazone / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity*; D051381:Rats
D010653:Phenylbutazone